Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.thelancet.com/journals/lanonc/article/PII" to "https://doi.org/10.1016/") |
Warner-admin (talk | contribs) |
||
| Line 1: | Line 1: | ||
| + | <span id="BackToTop"></span> | ||
| + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | ||
| + | [[#top|Back to Top]] | ||
| + | </div> | ||
{| class="wikitable" style="text-align:center; width:50%;" | {| class="wikitable" style="text-align:center; width:50%;" | ||
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' | !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' | ||
Revision as of 21:45, 17 September 2022
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
Unresectable, all lines of therapy
Placebo
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Ji et al. 2015 (SWOG S9005) | 1992-1998 | Phase 3 (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701